eXmoor

The company's business model is a hybrid, integrating deep consultancy experience with end-to-end manufacturing services. This dual capability allows eXmoor to guide clients, which range from small and medium-sized enterprises to larger biopharma companies, from early-stage strategy and process development through to Good Manufacturing Practice (GMP) production and commercialization. Revenue is generated by providing these services, which include process and analytical development, facility design, and GMP manufacturing of viral vectors, as well as autologous and allogeneic cell therapies. A significant milestone was achieved in August 2024, when the company received a Manufacturing and Import Authorisation (MIA) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new facility.

A key asset is eXmoor's 65,000 sq ft Cell and Gene Therapy Centre in Bristol, UK, which became operational in 2023. This purpose-built facility was funded in part by a £12 million investment in 2021 and a subsequent $35 million Series A round in 2023, with investors including MVM Partners and Kineticos Ventures. The facility houses four process-agnostic, Grade C GMP cleanrooms, an integrated fill-finish suite, and extensive quality control laboratories. It is designed for flexibility to support various CGT modalities and is equipped for future expansion. To extend its global reach, eXmoor has formed a strategic partnership with Kincell Bio, a US-based CDMO, to offer seamless manufacturing services across Europe and the United States.